MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mrinal M. Gounder, Gary K. Schwartz, Robin Lewis Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory Michael Cote, Robert G Maki, Hanna Kosela-Paterczyk, Dale Randall Shepard, Naisargee Shah, Richard Bryce, Robert Charles Doebele, Shreyaskumar Patel
Institutions: Memorial Sloan Kettering Cancer Center, Columbia University, Institute of Cancer Research, Royal Marsden Hospital, Sarcoma Oncology Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Dana-Farber Cancer Institute, Massachusetts General Hospital, Abramson Cancer Center, University of Pennsylvania, The Maria Sklodowska-Curie National Research Institute of Oncology, Cleveland Clinic, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281705492